This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Should Principal Value ETF (PY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PY
Is Principal Value ETF (PY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PY
Why Altria (MO) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Amgen, Altria Group, Uber Technologies, Microchip Technology, and Arista Networks
by Zacks Equity Research
Amgen, Altria Group, Uber Technologies, Microchip Technology, and Arista Networks are part of Zacks top Analyst Blog.
Top Research Reports for Amgen, Altria Group & Uber
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Altria Group, Inc. (MO), and Uber Technologies, Inc. (UBER).
Factors Setting the Tone for Dutch Bros (BROS) Q1 Earnings
by Zacks Equity Research
Dutch Bros' (BROS) first-quarter 2022 performance is likely to have benefited from strong consumer demand, new shop openings and expansion into new markets.
Is Invesco S&P 500 Equal Weight Consumer Staples ETF (RHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RHS
Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVY
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Should You Invest in the Invesco S&P 500 Equal Weight Consumer Staples ETF (RHS)?
by Zacks Equity Research
Sector ETF report for RHS
Altria (MO) Q1 Earnings & Revenues Top Estimates, Pricing Aids
by Zacks Equity Research
Altria Group's (MO) first-quarter 2022 results reflect increased revenues and earnings. Pricing remains an upside, though shipment volumes appear soft.
Altria (MO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 2.75% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for Altria Group (MO) in Q1 Earnings?
by Zacks Equity Research
Altria Group's (MO) first-quarter results are likely to reflect gains from pricing and oral tobacco products, while cigarette volumes are likely to have been soft.
Altria (MO) Stock Moves -1.77%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $55.53 in the latest trading session, marking a -1.77% move from the prior day.
Altria (MO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Altria (MO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $55.22, marking a +1.14% move from the previous day.
Post Holdings (POST) Provides Adjusted EBITDA View for FY22
by Zacks Equity Research
Post Holdings (POST) offers the adjusted EBITDA guidance for fiscal 2022, which takes into account the labor market and the input cost scenario and the latest avian influenza-related announcement.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $54.45 in the latest trading session, marking a +0.63% move from the prior day.
Coty (COTY) Up More Than 10% in 6 Months: More Room for Growth?
by Zacks Equity Research
Coty (COTY) has been gaining from its six core priorities and prudent alliances. The company's solid products and brands have been aiding, while cost inflation and supply-chain woes hurt.
The J.M. Smucker (SJM) Troubled by High Costs: Pricing Aids
by Zacks Equity Research
The J.M. Smucker Company (SJM) is battling cost-related challenges and supply-chain hurdles. However, revival in the Away from Home division and pricing actions bode well.
Sysco (SYY) Benefits From Recipe for Growth: Cost Woes Stay
by Zacks Equity Research
Sysco Corporation (SYY) is gaining on its Recipe for Growth plan, which involves five strategic priorities. However, high labor and transport costs pose threat to margins.
Medifast (MED) Troubled by High SG&A Costs, Gross Margin Woes
by Zacks Equity Research
Medifast (MED) has been seeing high SG&A expenses for a while now, mainly due to higher OPTAVIA commission costs. The company's gross margin has also been under pressure.
Philip Morris (PM) Benefits From Pricing Power & Focus on RRPs
by Zacks Equity Research
Philip Morris (PM) has been benefiting from its strong pricing power. Additionally, its focus on moving toward a majority smoke-free company bodes well.
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $52.72, moving +0.02% from the previous trading session.
Altria (MO) Gains on Strong Pricing & Oral Tobacco Products
by Zacks Equity Research
Altria Group (MO) has been benefiting from its strong pricing power. Additionally, a focus on oral tobacco products has been driving growth for the company.